Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Rigel Pharmaceuticals (NQ: RIGL )

22.07 +6.63 (+42.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rigel Pharmaceuticals

< Previous 1 2 3 4 5 Next >
Expert Ratings for Rigel Pharmaceuticals
  Rigel Pharmaceuticals (NASDAQ:RIGL) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Rigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing Pact
Via Benzinga
Rigel Pharmaceuticals: Q2 Earnings Insights
Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Outlook For Rigel Pharmaceuticals
Rigel Pharmaceuticals (NASDAQ:RIGL) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Rigel... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers 
Via Benzinga
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering. 
Via Benzinga
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. 
Via Benzinga
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown... 
Via Benzinga
3 Stocks Under $1 Insiders Are Buying
The Nasdaq Composite dropped by more than 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2022
Upgrades 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! We're starting off another day of trading with an overview of the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
18 Stocks Moving in Thursday's Pre-Market Session
Gainers View, Inc. (NASDAQ: VIEW) rose 18.5% to $2.05 in pre-market trading after declining 5% on Wednesday. 
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles 300 Points; HeartCore Enterprises Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Dow Jones dipping over 300 points on Wednesday. 
Via Benzinga
83 Biggest Movers From Yesterday
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 1%; Rigel Pharmaceuticals Shares Slide
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite adding around 50 points on Wednesday. 
Via Benzinga
Why Rigel Pharmaceuticals Shares Are Falling Today
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares are trading lower after the company announced data from the FORWARD Phase 3 clinical trial of Fostamatinib did not demonstrate statistical significance... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022
Upgrades 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback. 
Via Benzinga
Rigel Pharmaceuticals' Fostamatinib Flunks In Late-Stage Rare Blood Disorder Trial
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) shares are falling on disappointing data from the FORWARD Phase 3 trial of fostamatinib in patients with warm autoimmune hemolytic anemia (wAIHA). 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
Knight Therapeutics Secures Rights To Rigel's Fostamatinib In Latin America
Knight Therapeutics Inc. (TSX: GUD) (OTC: KHTRF) 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Recap: Rigel Pharmaceuticals Q1 Earnings
Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.